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ADAM proteases are type I transmembrane proteins with
extracellular metalloprotease domains. Like most ADAM
family members, ADAM8 (CD156a, MS2) is involved in
ectodomain shedding of membrane proteins and is linked
to neuroinflammation and neurodegeneration. To iden-
tify potential substrates released under these pathologic
conditions, we screened 10-mer peptides representing
amino acid sequences from extracellular domains of vari-
ous membrane proteins using the ProteaseSpot™ system.
A soluble ADAM8 protease containing pro- and metallo-
protease domain was expressed in E. coli and purified as
active protease due to autocatalytic prodomain removal.
From 34 peptides tested in the peptide cleavage assay, sig-
nificant cleavage by soluble ADAM8 was observed for 14
peptides representing membrane proteins with functions
in inflammation and neurodegeneration, among them
the beta amyloid precursor protein (APP) and the Tumor
Necrosis Factor alpha Receptor type I (TNFRI). The in vivo
relevance of the ProteaseSpot™ method was confirmed by
cleavage of full length APP with ADAM8 in human embry-
onic kidney 293 cells expressing tagged APP. ADAM8
cleaved APP with similar efficiency as ADAM10, whereas
inactive ADAM8 mutant did not. Cleavage of TNFRI was
assessed in primary cell lines deficient in ADAM8 and
revealed a gene dosage-dependent effect. Exchanging
amino acids at defined positions in the cleavage sequence
of myelin basic protein (MBP) revealed sequence criteria
for ADAM8 cleavage. Taken together, we identified novel
substrates that could be cleaved by ADAM8 in vivo under
pathologic conditions.
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